Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$54.97 USD
+0.44 (0.81%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.95 -0.02 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.97 USD
+0.44 (0.81%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.95 -0.02 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Zacks News
Does Cytokinetics (CYTK) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 62.8% upside potential for Cytokinetics (CYTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Dips 20% so Far in 2023 on Setbacks
by Zacks Equity Research
Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -18.85% and 73.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback
by Zacks Equity Research
Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.
Is a Surprise Coming for Cytokinetics (CYTK) This Earnings Season?
by Zacks Equity Research
Cytokinetics (CYTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates
by Ekta Bagri
We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -7.56% and 11.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 8.74% and 1.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Cytokinetics (CYTK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cytokinetics (CYTK) and Humana (HUM) have performed compared to their sector so far this year.
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
by Zacks Equity Research
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?
by Zacks Equity Research
Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cytokinetics (CYTK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -33.33% and 78.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Cytokinetics (CYTK) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Cytokinetics (CYTK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Cytokinetics (CYTK)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Cytokinetics (CYTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Cytokinetics' (CYTK) Aficamten Gets Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.